HYHideko Yamamoto

Hideko Yamamoto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hideko Yamamoto has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Hidemi Goto

    Department of Gastroenteralogy, Nagoya University Graduate School of Medicine, 65 Tsuramai‐cho, Showa‐ku, Nagoya 466‐8560, Japan

    1 shared publication
  • Hiroki Kawai

    Department of Endoscopy, Aichi Cancer Center Hospital, 1‐1 Kanokoden, Chikasu‐ku, Nagoya 464‐8681

    1 shared publication
  • Keitaro Matsuo

    Division of Cancer Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan

    1 shared publication
  • Masahiro Tajika

    Department of Endoscopy, Aichi Cancer Center Hospital, 1‐1 Kanokoden, Chikasu‐ku, Nagoya 464‐8681

    1 shared publication
  • Naoki Ohmiya

    Department of Gastroenteralogy, Nagoya University Graduate School of Medicine, 65 Tsuramai‐cho, Showa‐ku, Nagoya 466‐8560, Japan

    1 shared publication
  • Shigeo Nakamura

    Department of Pathology and Clinical Laboratories, Nagoya University Hospital, 65 Tsuramai‐cho, Showa‐ku, Nagoya 466‐8560

    1 shared publication

Latest Publications

  • Open Access

    Significance of CXCR3 expression in gastric low‐grade B‐cell lymphoma of mucosa‐associated lymphoid tissue type for predicting responsiveness to Helicobacter pylori eradication

    by Hideko Yamamoto, Tsuneya Nakamura, Keitaro Matsuo, Masahiro Tajika, Hiroki Kawai, Naoki Ohmiya, Yasumasa Niwa, Hidemi Goto, Shigeo Nakamura

    Gastric mucosa‐associated lymphoid tissue (MALT) lymphoma is a distinct low‐grade lymphoma that often regresses upon Helicobacter pylori eradication. It was reported that the chemokine receptor CXCR3 is expressed not only on activated T cells, but also on MALT lymphoma cells, and that CXCR3‐positive B lymphocytes migrate or home to the MALT of MALT lymphoma. In the present study, we aimed to elucidate the correlation between CXCR3 expression and the clinicopathological features of gastric MALT lymphoma, and to determine whether CXCR3 expression was predictive of responsiveness to H. pylori eradication. Sixty‐seven patients with gastric MALT lymphoma in a single‐center study were treated with H. pylori eradication therapy. We evaluated the correlation of CXCR3 expression with response to H. pylori eradication therapy by logistic regression stratified according to potential confounders. Immunohistochemical analysis revealed that 28 of 67 cases (42%) were positive for CXCR3 expression. CXCR3 expression was significantly more prevalent in those without H. pylori infection, advanced‐stage disease, and in those with API2–MALT1 fusion. In overall analysis, those with CXCR3 expression showed a significantly increased risk of non‐responsiveness to H. pylori eradication therapy (odds ratio = 28.6; 95% confidence interval 5.70–143.4) compared to those without CXCR3 expression. This higher risk was observed consistently regardless of sex, API2–MALT1 fusion, H. pylori infection, or clinical stage. We showed that CXCR3 expression was an independent predictive factor for non‐responsiveness to H. pylori eradication therapy in patients with gastric MALT lymphoma. (Cancer Sci 2008; 99: 1769–1773)